The FDA has approved Pfizer’s bevacizumab biosimilar, bevacizumab-bvzr, referencing Avastin.
The FDA has approved Pfizer’s bevacizumab biosimilar, bevacizumab-bvzr, referencing Avastin. The biosimilar will be sold as Zirabev. The drug has been approved for the treatment of metastatic colorectal cancer, recurrent or metastatic nonsquamous non—small cell lung cancer (NSCLC), recurrent glioblastoma, metastatic renal cell carcinoma, and persistent, recurrent, or metastatic cervical cancer.
“Biosimilars like Zirabev can help increase access to impactful therapies, driving market competition that may ultimately lower costs and help address the diverse needs of patients living with cancer,” Andy Schmeltz, global president of Pfizer Oncology, said in a statement. “We are proud to add Zirabev to our growing oncology portfolio for US patients living with a wide variety of tumor types.”
Among the data Pfizer generated in support of the biosimilar’s approval were those from the REFLECTIONS B7391003 study, a comparative, confirmatory safety and efficacy study of the biosimilar versus the reference bevacizumab. The trial enrolled 719 patients with advanced nonsquamous NSCLC. The study demonstrated equivalence in the primary end point of objective response rate of the biosimilar versus the reference when taken in combination with carboplatin/paclitaxel for first-line treatment of NSCLC.
Additionally, a phase 1 pharmacokinetic (PD) study1 of the biosimilar was conducted in 102 healthy males volunteers. In the double-blind study, the volunteers received single 5 mg per kg intravenous doses of either the biosimilar, the EU-licensed reference product, or the US-licensed reference product. PK similarity was achieved if 90% CIs for the test-to-reference ratios of the maximum serum concentration, area under the serum concentration—time curve from zero to infinity, and from zero to time of last quantifiable concentration fell within the 80% to 125% bioequivalence acceptance window. The 90% CIs for all 3 parameters fell within the prespecified margin.
Pfizer’s biosimilar is also approved in the European Union; Zirabev earned the European Commission’s approval in February 2019 after having received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use in December 2018.
Pfizer’s biosimilar joins Amgen’s Mvasi in the ranks of FDA-approved bevacizumab biosimilars, although it remains to be seen which product will be first to the US market; while Mvasi was approved in the United States in 2017, it has not yet been launched.
Reference
1. Knight B, Rassam D, Liao S, Ewesuedo R. A phase I pharmacokinetics study comparing PF-06439535 (a potential biosimilar) with bevacizumab in healthy male volunteers. Cancer Chemother Pharmacol. 2016;77(4):839-46. doi: 10.1007/s00280-016-3001-2.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.